Download PDF
Semin Respir Crit Care Med 2010; 31(6): 723-733
DOI: 10.1055/s-0030-1269831
© Thieme Medical Publishers

Management of the Patient with a Malignant Pleural Effusion

John E. Heffner1 , 2
  • 1Providence Portland Medical Center, Portland, Oregon
  • 2Department of Medicine, Oregon Health and Science Center, Portland, Oregon
Further Information

Publication History

Publication Date:
06 January 2011 (online)

    Permissions and Reprints

ABSTRACT

A malignant pleural effusion (MPE) establishes an incurable stage of a malignancy. Median survival after detection of an MPE is 4 to 6 months in general populations of patients with cancer. Management of MPE centers on palliation of symptoms because no available treatments prolong survival. Mismanagement of MPE, however, can shorten survival and add to patients' burden of disease. Appropriate management requires a multidisciplinary approach with competency in existing treatment modalities to allow individualization of care. Although few prospective studies exist to guide clinical decisions, treating centers should present to patients the relative risks and benefits of different approaches and ensure that their institution's clinical outcomes in managing MPE match those of best clinical practices reported in the literature. Treatment of MPE is moving toward less interventional approaches that can manage patients in ambulatory settings thereby decreasing cost, discomfort, and time away from home for inpatient care.

KEYWORDS

Malignant pleural effusion - pleural disease - cancer - pleurodesis

REFERENCES

  • 1 Heffner J E, Nietert P J, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions.  Chest. 2000;  117 79-86
    CrossrefPubMedGoogle Scholar
  • 2 Gonzalez A V, Bezwada V, Beamis Jr JFJ, Villanueva A G. Lung injury following thoracoscopic talc insufflation: experience of a single North American center.  Chest. 2010;  137 1375-1381
    CrossrefPubMedGoogle Scholar
  • 3 Goldstraw P, Crowley J, Chansky K International Association for the Study of Lung Cancer International Staging Committee et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.  J Thorac Oncol. 2007;  2 706-714
    CrossrefPubMedGoogle Scholar
  • 4 Heffner J E. Diagnosis and management of malignant pleural effusions.  Respirology. 2008;  13 5-20
    PubMedGoogle Scholar
  • 5 Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.  Chest. 2005;  128 1431-1435
    CrossrefPubMedGoogle Scholar
  • 6 Rubio E R, Chang E E, Kovitz K L. Thoracoscopic management of pleural effusions in Kaposi's sarcoma: a rapid and effective alternative for diagnosis and treatment.  South Med J. 2002;  95 919-921
    PubMedGoogle Scholar
  • 7 Fujita A, Takabatake H, Tagaki S, Sekine K. Combination chemotherapy in patients with malignant pleural effusions from non-small cell lung cancer: cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support.  Chest. 2001;  119 340-343
    CrossrefPubMedGoogle Scholar
  • 8 Matsumoto Y, Nomura K, Ueda K et al.. Human herpesvirus 8-negative malignant effusion lymphoma: a distinct clinical entity and successful treatment with rituximab.  Leuk Lymphoma. 2005;  46 415-419
    CrossrefPubMedGoogle Scholar
  • 9 Das S K, Saha S K, Das A, Halder A K, Banerjee S N, Chakraborty M. A study of comparison of efficacy and safety of talc and povidone iodine for pleurodesis of malignant pleural effusions.  J Indian Med Assoc. 2008;  106 589-590, 592
    PubMedGoogle Scholar
  • 10 Dresler C M, Olak J, Herndon II J E Cooperative Groups Cancer and Leukemia Group B et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.  Chest. 2005;  127 909-915
    CrossrefPubMedGoogle Scholar
  • 11 Ozyurtkan M O, Balci A E, Cakmak M. Predictors of mortality within three months in the patients with malignant pleural effusion.  Eur J Intern Med. 2010;  21 30-34
    CrossrefPubMedGoogle Scholar
  • 12 Das D K. Serous effusions in malignant lymphomas: a review.  Diagn Cytopathol. 2006;  34 335-347
    CrossrefPubMedGoogle Scholar
  • 13 Villena V, Pérez V, Pozo F et al.. Amylase levels in pleural effusions: a consecutive unselected series of 841 patients.  Chest. 2002;  121 470-474
    CrossrefPubMedGoogle Scholar
  • 14 Bielsa S, Salud A, Martínez M et al.. Prognostic significance of pleural fluid data in patients with malignant effusion.  Eur J Intern Med. 2008;  19 334-339
    CrossrefPubMedGoogle Scholar
  • 15 Bielsa S, Esquerda A, Salud A et al.. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions.  Eur J Intern Med. 2009;  20 383-386
    CrossrefPubMedGoogle Scholar
  • 16 Jiménez D, Díaz G, Gil D et al.. Etiology and prognostic significance of massive pleural effusions.  Respir Med. 2005;  99 1183-1187
    CrossrefPubMedGoogle Scholar
  • 17 Duysinx B, Corhay J L, Larock M P et al.. Prognostic value of metabolic imaging in non-small cell lung cancers with neoplasic pleural effusion.  Nucl Med Commun. 2008;  29 982-986
    CrossrefPubMedGoogle Scholar
  • 18 Burrows C M, Mathews W C, Colt H G. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease.  Chest. 2000;  117 73-78
    CrossrefPubMedGoogle Scholar
  • 19 Bernard A, de Dompsure R B, Hagry O, Favre J P. Early and late mortality after pleurodesis for malignant pleural effusion.  Ann Thorac Surg. 2002;  74 213-217
    CrossrefPubMedGoogle Scholar
  • 20 Steger V, Mika U, Toomes H et al.. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses.  Ann Thorac Surg. 2007;  83 1940-1945
    CrossrefPubMedGoogle Scholar
  • 21 Heidecker J, Huggins J T, Sahn S A, Doelken P. Pathophysiology of pneumothorax following ultrasound-guided thoracentesis.  Chest. 2006;  130(4) 1173-1184
    CrossrefPubMedGoogle Scholar
  • 22 Ponrartana S, Laberge J M, Kerlan R K, Wilson M W, Gordon R L. Management of patients with “ex vacuo” pneumothorax after thoracentesis.  Acad Radiol. 2005;  12 980-986
    CrossrefPubMedGoogle Scholar
  • 23 Feller-Kopman D. Therapeutic thoracentesis: the role of ultrasound and pleural manometry.  Curr Opin Pulm Med. 2007;  13 312-318
    CrossrefPubMedGoogle Scholar
  • 24 Huggins J T, Sahn S A, Heidecker J, Ravenel J G, Doelken P. Characteristics of trapped lung: pleural fluid analysis, manometry, and air-contrast chest CT.  Chest. 2007;  131 206-213
    CrossrefPubMedGoogle Scholar
  • 25 Heffner J E, Nietert P J, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data.  Chest. 2000;  117 87-95
    CrossrefPubMedGoogle Scholar
  • 26 Heffner J E, Heffner J N, Brown L K. Multilevel and continuous pleural fluid pH likelihood ratios for evaluating malignant pleural effusions.  Chest. 2003;  123 1887-1894
    CrossrefPubMedGoogle Scholar
  • 27 Crnjac A, Sok M, Kamenik M. Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma.  Eur J Cardiothorac Surg. 2004;  26 432-436
    CrossrefPubMedGoogle Scholar
  • 28 Antunes G, Neville E, Duffy J, Ali N. Pleural Diseases Group, Standards of Care Committee, British Thoracic Society . BTS guidelines for the management of malignant pleural effusions.  Thorax. 2003;  58(Suppl 2) ii29-ii38
    CrossrefPubMedGoogle Scholar
  • 29 Marrazzo A, Noto A, Casà L et al.. Video-thoracoscopic surgical pleurodesis in the management of malignant pleural effusion: the importance of an early intervention.  J Pain Symptom Manage. 2005;  30 75-79
    CrossrefPubMedGoogle Scholar
  • 30 Barnes T W, Morgenthaler T I, Olson E J, Hesley G K, Decker P A, Ryu J H. Sonographically guided thoracentesis and rate of pneumothorax.  J Clin Ultrasound. 2005;  33 442-446
    CrossrefPubMedGoogle Scholar
  • 31 Huggins J T, Doelken P. Pleural manometry.  Clin Chest Med. 2006;  27 229-240
    CrossrefPubMedGoogle Scholar
  • 32 Feller-Kopman D, Walkey A, Berkowitz D, Ernst A. The relationship of pleural pressure to symptom development during therapeutic thoracentesis.  Chest. 2006;  129 1556-1560
    CrossrefPubMedGoogle Scholar
  • 33 Maskell N A, Butland R J. Pleural Diseases Group, Standards of Care Committee, British Thoracic Society . BTS guidelines for the investigation of a unilateral pleural effusion in adults.  Thorax. 2003;  58(Suppl 2) ii8-ii17
    PubMedGoogle Scholar
  • 34 Lee Y C, Baumann M H, Maskell N A et al.. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists.  Chest. 2003;  124 2229-2238
    CrossrefPubMedGoogle Scholar
  • 35 Medford A R, Maskell N A. A national survey of oncologist and chest physicians' attitudes towards empirical anti-oestrogen therapy, early pleurodesis and preference of sclerosing agent in malignant breast and ovarian pleural disease.  Palliat Med. 2005;  19 430-431
    PubMedGoogle Scholar
  • 36 Saffran L, Ost D E, Fein A M, Schiff M J. Outpatient pleurodesis of malignant pleural effusions using a small-bore pigtail catheter.  Chest. 2000;  118 417-421
    CrossrefPubMedGoogle Scholar
  • 37 Sartori S, Tombesi P, Tassinari D et al.. Sonographically guided small-bore chest tubes and sonographic monitoring for rapid sclerotherapy of recurrent malignant pleural effusions.  J Ultrasound Med. 2004;  23 1171-1176
    PubMedGoogle Scholar
  • 38 Caglayan B, Torun E, Turan D et al.. Efficacy of iodopovidone pleurodesis and comparison of small-bore catheter versus large-bore chest tube.  Ann Surg Oncol. 2008;  15 2594-2599
    CrossrefPubMedGoogle Scholar
  • 39 Spiegler P A, Hurewitz A N, Groth M L. Rapid pleurodesis for malignant pleural effusions.  Chest. 2003;  123 1895-1898
    CrossrefPubMedGoogle Scholar
  • 40 Yildirim E, Dural K, Yazkan R et al.. Rapid pleurodesis in symptomatic malignant pleural effusion.  Eur J Cardiothorac Surg. 2005;  27 19-22
    CrossrefPubMedGoogle Scholar
  • 41 Marom E M, Erasmus J J, Herndon II J E, Zhang C, McAdams H P. Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions.  AJR Am J Roentgenol. 2002;  179 105-108
    PubMedGoogle Scholar
  • 42 Terra R M, Junqueira J J, Teixeira L R, Vargas F S, Pêgo-Fernandes P M, Jatene F B. Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis?.  Chest. 2009;  136 361-368
    CrossrefPubMedGoogle Scholar
  • 43 Mager H J, Maesen B, Verzijlbergen F, Schramel F. Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis.  Lung Cancer. 2002;  36 77-81
    CrossrefPubMedGoogle Scholar
  • 44 Dryzer S R, Allen M L, Strange C, Sahn S A. A comparison of rotation and nonrotation in tetracycline pleurodesis.  Chest. 1993;  104 1763-1766
    CrossrefPubMedGoogle Scholar
  • 45 Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review.  Eur J Cardiothorac Surg. 2006;  29 829-838
    CrossrefPubMedGoogle Scholar
  • 46 Teixeira L R, Vargas F S, Acencio M M et al.. Influence of antiinflammatory drugs (methylprednisolone and diclofenac sodium) on experimental pleurodesis induced by silver nitrate or talc.  Chest. 2005;  128 4041-4045
    CrossrefPubMedGoogle Scholar
  • 47 Teixeira L R, Wu W, Chang D S, Light R W. The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits.  Chest. 2002;  121 216-219
    CrossrefPubMedGoogle Scholar
  • 48 Xie C, Teixeira L R, McGovern J P, Light R W. Systemic corticosteroids decrease the effectiveness of talc pleurodesis.  Am J Respir Crit Care Med. 1998;  157(5 Pt 1) 1441-1444
    PubMedGoogle Scholar
  • 49 Haddad F J, Younes R N, Gross J L, Deheinzelin D. Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial.  World J Surg. 2004;  28 749-753, discussion 753–754
    CrossrefPubMedGoogle Scholar
  • 50 Goodman A, Davies C W. Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: a randomised trial.  Lung Cancer. 2006;  54 51-55
    CrossrefPubMedGoogle Scholar
  • 51 Arapis K, Caliandro R, Stern J B, Girard P, Debrosse D, Gossot D. Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients.  Surg Endosc. 2006;  20 919-923
    CrossrefPubMedGoogle Scholar
  • 52 Brega-Massone P P, Lequaglie C, Magnani B, Ferro F, Cataldo I. Chemical pleurodesis to improve patients' quality of life in the management of malignant pleural effusions: the 15 year experience of the National Cancer Institute of Milan.  Surg Laparosc Endosc Percutan Tech. 2004;  14 73-79
    PubMedGoogle Scholar
  • 53 Cardillo G, Facciolo F, Carbone L et al.. Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions.  Eur J Cardiothorac Surg. 2002;  21 302-305, discussion 305–306
    CrossrefPubMedGoogle Scholar
  • 54 Crnjac A. The significance of thoracoscopic mechanical pleurodesis for the treatment of malignant pleural effusions.  Wien Klin Wochenschr. 2004;  116(Suppl 2) 28-32
    PubMedGoogle Scholar
  • 55 Debeljak A, Kecelj P, Triller N et al.. Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions.  J BUON. 2006;  11 463-467
    PubMedGoogle Scholar
  • 56 Gasparri R, Leo F, Veronesi G et al.. Video-assisted management of malignant pleural effusion in breast carcinoma.  Cancer. 2006;  106 271-276
    CrossrefPubMedGoogle Scholar
  • 57 Trotter D, Aly A, Siu L, Knight S. Video-assisted thoracoscopic (VATS) pleurodesis for malignant effusion: an Australian teaching hospital's experience.  Heart Lung Circ. 2005;  14 93-97
    CrossrefPubMedGoogle Scholar
  • 58 Casal R F, Eapen G A, Morice R C, Jimenez C A. Medical thoracoscopy.  Curr Opin Pulm Med. 2009;  15 313-320
    CrossrefPubMedGoogle Scholar
  • 59 Law W L, Chan J W, Lee S et al.. Pleuroscopy: our initial experience in Hong Kong.  Hong Kong Med J. 2008;  14 178-184
    PubMedGoogle Scholar
  • 60 Lee P, Colt H G. Rigid and semirigid pleuroscopy: the future is bright.  Respirology. 2005;  10 418-425
    CrossrefPubMedGoogle Scholar
  • 61 Ernst A, Hersh C P, Herth F et al.. A novel instrument for the evaluation of the pleural space: an experience in 34 patients.  Chest. 2002;  122 1530-1534
    CrossrefPubMedGoogle Scholar
  • 62 Munavvar M, Khan M A, Edwards J, Waqaruddin Z, Mills J. The autoclavable semirigid thoracoscope: the way forward in pleural disease?.  Eur Respir J. 2007;  29 571-574
    CrossrefPubMedGoogle Scholar
  • 63 Katlic M R. Video-assisted thoracic surgery utilizing local anesthesia and sedation.  Eur J Cardiothorac Surg. 2006;  30 529-532
    CrossrefPubMedGoogle Scholar
  • 64 Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions.  Cochrane Database Syst Rev. 2004;  (1) CD002916
    PubMedGoogle Scholar
  • 65 Schulze M, Boehle A S, Kurdow R, Dohrmann P, Henne-Bruns D. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients.  Ann Thorac Surg. 2001;  71 1809-1812
    CrossrefPubMedGoogle Scholar
  • 66 Ukale V, Agrenius V, Hillerdal G, Mohlkert D, Widström O. Pleurodesis in recurrent pleural effusions: a randomized comparison of a classical and a currently popular drug.  Lung Cancer. 2004;  43 323-328
    CrossrefPubMedGoogle Scholar
  • 67 Paschoalini MdaS, Vargas F S, Marchi E et al.. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions.  Chest. 2005;  128 684-689
    CrossrefPubMedGoogle Scholar
  • 68 Kuzdzał J, Sładek K, Wasowski D et al.. Talc powder vs doxycycline in the control of malignant pleural effusion: a prospective, randomized trial.  Med Sci Monit. 2003;  9 PI54-PI59
    PubMedGoogle Scholar
  • 69 Ong K C, Indumathi V, Raghuram J, Ong Y Y. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions.  Respirology. 2000;  5 99-103
    CrossrefPubMedGoogle Scholar
  • 70 Brant A, Eaton T. Serious complications with talc slurry pleurodesis.  Respirology. 2001;  6 181-185
    CrossrefPubMedGoogle Scholar
  • 71 de Campos J R, Vargas F S, de Campos Werebe E et al.. Thoracoscopy talc poudrage: a 15-year experience.  Chest. 2001;  119 801-806
    CrossrefPubMedGoogle Scholar
  • 72 Bouchama A, Chastre J, Gaudichet A, Soler P, Gibert C. Acute pneumonitis with bilateral pleural effusion after talc pleurodesis.  Chest. 1984;  86 795-797
    CrossrefPubMedGoogle Scholar
  • 73 Peek H, van der Bruggen W, Limonard G. Pleural FDG uptake more than a decade after talc pleurodesis.  Case Report Med. 2009;  2009 650864
    PubMedGoogle Scholar
  • 74 Ahmadzadehfar H, Palmedo H, Strunk H, Biersack H J, Habibi E, Ezziddin S. False positive 18F-FDG-PET/CT in a patient after talc pleurodesis.  Lung Cancer. 2007;  58 418-421
    CrossrefPubMedGoogle Scholar
  • 75 Ferrer J, Montes J F, Villarino M A, Light R W, García-Valero J. Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis.  Chest. 2002;  122 1018-1027
    CrossrefPubMedGoogle Scholar
  • 76 Froudarakis M E, Klimathianaki M, Pougounias M. Systemic inflammatory reaction after thoracoscopic talc poudrage.  Chest. 2006;  129 356-361
    CrossrefPubMedGoogle Scholar
  • 77 Rossi V F, Vargas F S, Marchi E et al.. Acute inflammatory response secondary to intrapleural administration of two types of talc.  Eur Respir J. 2010;  35 396-401
    CrossrefPubMedGoogle Scholar
  • 78 Viallat J R, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions: a review of 360 cases.  Chest. 1996;  110 1387-1393
    CrossrefPubMedGoogle Scholar
  • 79 Weissberg D, Ben-Zeev I. Talc pleurodesis: experience with 360 patients.  J Thorac Cardiovasc Surg. 1993;  106 689-695
    PubMedGoogle Scholar
  • 80 Noppen M. Who's (still) afraid of talc?.  Eur Respir J. 2007;  29 619-621
    CrossrefPubMedGoogle Scholar
  • 81 Janssen J P, Collier G, Astoul P et al.. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study.  Lancet. 2007;  369 1535-1539
    CrossrefPubMedGoogle Scholar
  • 82 Kuzniar T J, Blum M G, Kasibowska-Kuzniar K, Mutlu G M. Predictors of acute lung injury and severe hypoxemia in patients undergoing operative talc pleurodesis.  Ann Thorac Surg. 2006;  82 1976-1981
    CrossrefPubMedGoogle Scholar
  • 83 Dikensoy O, Light R W. Alternative widely available, inexpensive agents for pleurodesis.  Curr Opin Pulm Med. 2005;  11 340-344
    CrossrefPubMedGoogle Scholar
  • 84 van den Toorn L M, Schaap E, Surmont V F, Pouw E M, van der Rijt K C, van Klaveren R J. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter.  Lung Cancer. 2005;  50 123-127
    CrossrefPubMedGoogle Scholar
  • 85 Putnam Jr J B, Light R W, Rodriguez R M et al.. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions.  Cancer. 1999;  86 1992-1999
    CrossrefPubMedGoogle Scholar
  • 86 Putnam Jr J B, Walsh G L, Swisher S G et al.. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter.  Ann Thorac Surg. 2000;  69 369-375
    PubMedGoogle Scholar
  • 87 Pollak J S, Burdge C M, Rosenblatt M, Houston J P, Hwu W J, Murren J. Treatment of malignant pleural effusions with tunneled long-term drainage catheters.  J Vasc Interv Radiol. 2001;  12 201-208
    CrossrefPubMedGoogle Scholar
  • 88 Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion.  Chest. 2006;  129 362-368
    CrossrefPubMedGoogle Scholar
  • 89 Pien G W, Gant M J, Washam C L, Sterman D H. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion.  Chest. 2001;  119 1641-1646
    CrossrefPubMedGoogle Scholar
  • 90 Musani A I, Haas A R, Seijo L, Wilby M, Sterman D H. Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters.  Respiration. 2004;  71 559-566
    CrossrefPubMedGoogle Scholar
  • 91 Ohm C, Park D, Vogen M et al.. Use of an indwelling pleural catheter compared with thorascopic talc pleurodesis in the management of malignant pleural effusions.  Am Surg. 2003;  69 198-202, discussion 202
    PubMedGoogle Scholar
  • 92 Sioris T, Sihvo E, Salo J, Räsänen J, Knuuttila A. Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis.  Eur J Surg Oncol. 2009;  35 546-551
    CrossrefPubMedGoogle Scholar
  • 93 Spector M, Pollak J S. Management of malignant pleural effusions.  Semin Respir Crit Care Med. 2008;  29 405-413
    Article in Thieme ConnectPubMedGoogle Scholar
  • 94 Thornton R H, Miller Z, Covey A M et al.. Tunneled pleural catheters for treatment of recurrent malignant pleural effusion following failed pleurodesis.  J Vasc Interv Radiol. 2010;  21 696-700
    CrossrefPubMedGoogle Scholar
  • 95 Efthymiou C A, Masudi T, Thorpe J A, Papagiannopoulos K. Malignant pleural effusion in the presence of trapped lung: five-year experience of PleurX tunnelled catheters.  Interact Cardiovasc Thorac Surg. 2009;  9 961-964
    CrossrefPubMedGoogle Scholar
  • 96 Warren W H, Kim A W, Liptay M J. Identification of clinical factors predicting PleurX catheter removal in patients treated for malignant pleural effusion.  Eur J Cardiothorac Surg. 2008;  33 89-94
    CrossrefPubMedGoogle Scholar
  • 97 Warren W H, Kim A W, Liptay M J. Identification of clinical factors predicting PleurX catheter removal in patients treated for malignant pleural effusion.  Eur J Cardiothorac Surg. 2008;  33 89-94
    CrossrefPubMedGoogle Scholar
  • 98 Pollak J S. Malignant pleural effusions: treatment with tunneled long-term drainage catheters.  Curr Opin Pulm Med. 2002;  8 302-307
    CrossrefPubMedGoogle Scholar
  • 99 Murthy S C, Okereke I, Mason D P, Rice T W. A simple solution for complicated pleural effusions.  J Thorac Oncol. 2006;  1 697-700
    CrossrefPubMedGoogle Scholar
  • 100 Warren W. Talc pleurodesis for malignant pleural effusions is preferred over the PleurX catheter (contrary position).  Ann Surg Oncol. 2007;  14 2700-2701
    CrossrefPubMedGoogle Scholar
  • 101 Stather D R, Tremblay A. Use of tunneled pleural catheters for outpatient treatment of malignant pleural effusions.  Curr Opin Pulm Med. 2007;  13 328-333
    CrossrefPubMedGoogle Scholar
  • 102 Bazerbashi S, Villaquiran J, Awan M Y, Unsworth-White M J, Rahamim J, Marchbank A. Ambulatory intercostal drainage for the management of malignant pleural effusion: a single center experience.  Ann Surg Oncol. 2009;  16 3482-3487
    CrossrefPubMedGoogle Scholar
  • 103 Olden A M, Holloway R. Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis.  J Palliat Med. 2010;  13 59-65
    CrossrefPubMedGoogle Scholar
  • 104 Antevil J L, Putnam Jr JBJ. Talc pleurodesis for malignant effusions is preferred over the pleurx catheter (pro position).  Ann Surg Oncol. 2007;  14 2698-2699
    CrossrefPubMedGoogle Scholar
  • 105 Wachsman A M, Hoffer E K, Forauer A R, Silas A M, Gemery J M. Tension pneumothorax after placement of a tunneled pleural drainage catheter in a patient with recurrent malignant pleural effusions.  Cardiovasc Intervent Radiol. 2007;  30 531-533
    CrossrefPubMedGoogle Scholar
  • 106 Janes S M, Rahman N M, Davies R J, Lee Y C. Catheter-tract metastases associated with chronic indwelling pleural catheters.  Chest. 2007;  131 1232-1234
    CrossrefPubMedGoogle Scholar
  • 107 Genc O, Petrou M, Ladas G, Goldstraw P. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions.  Eur J Cardiothorac Surg. 2000;  18 143-146
    CrossrefPubMedGoogle Scholar
  • 108 Artemiou O, Marta G M, Klepetko W, Wolner E, Müller M R. Pleurovenous shunting in the treatment of nonmalignant pleural effusion.  Ann Thorac Surg. 2003;  76 231-233
    CrossrefPubMedGoogle Scholar
  • 109 American Academy of Hospice and Palliative Medicine . National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for quality palliative care, executive summary.  J Palliat Med. 2004;  7 611-627
    CrossrefPubMedGoogle Scholar
  • 110 Word Health Organization definition of palliative care. World Health Organization programmes and projects (online). 2010. Available at: http://www.who.int/cancer/palliative/definition/en/ Accessed November 17, 2010
    Google Scholar
  • 111 Kilic D, Akay H, Kavukçu S et al.. Management of recurrent malignant pleural effusion with chemical pleurodesis.  Surg Today. 2005;  35 634-638
    CrossrefPubMedGoogle Scholar
  • 112 Stefani A, Natali P, Casali C, Morandi U. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion: a prospective comparative study.  Eur J Cardiothorac Surg. 2006;  30 827-832
    CrossrefPubMedGoogle Scholar
  • 113 Porcel J M, Salud A, Nabal M, Vives M, Esquerda A, Rodríguez-Panadero F. Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions.  Support Care Cancer. 2006;  14 475-478
    CrossrefPubMedGoogle Scholar
  • 114 Heffner J E, Standerfer R J, Torstveit J, Unruh L. Clinical efficacy of doxycycline for pleurodesis.  Chest. 1994;  105 1743-1747
    CrossrefPubMedGoogle Scholar
  • 115 Sartori S, Tassinari D, Ceccotti P et al.. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions.  J Clin Oncol. 2004;  22 1228-1233
    CrossrefPubMedGoogle Scholar
  • 116 Moffett M J, Ruckdeschel J C. Bleomycin and tetracycline in malignant pleural effusions: a review.  Semin Oncol. 1992;  19(2, Suppl 5) 59-62, discussion 62–63
    PubMedGoogle Scholar
  • 117 Stiksa G, Korsgaard R, Simonsson B G. Treatment of recurrent pleural effusion by pleurodesis with quinacrine: comparison between instillation by repeated thoracenteses and by tube drainage.  Scand J Respir Dis. 1979;  60 197-205
    PubMedGoogle Scholar
  • 118 Bayly T C, Kisner D L, Sybert A, Macdonald J S, Tsou E, Schein P S. Tetracycline and quinacrine in the control of malignant pleural effusions: a randomized trial.  Cancer. 1978;  41 1188-1192
    CrossrefPubMedGoogle Scholar
  • 119 Koldsland S, Svennevig J L, Lehne G, Johnson E. Chemical pleurodesis in malignant pleural effusions: a randomised prospective study of mepacrine versus bleomycin.  Thorax. 1993;  48 790-793
    CrossrefPubMedGoogle Scholar
  • 120 Banerjee A K, Willetts I, Robertson J F, Blamey R W. Pleural effusion in breast cancer: a review of the Nottingham experience.  Eur J Surg Oncol. 1994;  20 33-36
    PubMedGoogle Scholar
  • 121 Olivares-Torres C A, Laniado-Laborín R, Chávez-García C, León-Gastelum C, Reyes-Escamilla A, Light R W. Iodopovidone pleurodesis for recurrent pleural effusions.  Chest. 2002;  122 581-583
    CrossrefPubMedGoogle Scholar
  • 122 Agarwal R, Aggarwal A N, Gupta D. Efficacy and safety of iodopovidone pleurodesis through tube thoracostomy.  Respirology. 2006;  11 105-108
    CrossrefPubMedGoogle Scholar
  • 123 Agarwal R, Aggarwal A N, Gupta D, Jindal S K. Efficacy and safety of iodopovidone in chemical pleurodesis: a meta-analysis of observational studies.  Respir Med. 2006;  100 2043-2047
    CrossrefPubMedGoogle Scholar
  • 124 Kelly-Garcia J, Roman-Berumen J F, Ibarra-Perez C. Iodopovidone and bleomycin pleurodesis for effusions due to malignant epithelial neoplasms.  Arch Med Res. 1997;  28 583-585
    PubMedGoogle Scholar
  • 125 Agarwal R. Iodopovidone: an inexpensive and effective agent for chemical pleurodesis.  Lung Cancer. 2007;  55 253-254
    CrossrefPubMedGoogle Scholar
  • 126 Dey A, Bhuniya S, Datta Chaudhuri A et al.. Iodopovidone pleurodesis: experience of a tertiary hospital in Kolkata.  Singapore Med J. 2010;  51 163-165
    PubMedGoogle Scholar
  • 127 Foresti V. Intrapleural Corynebacterium parvum for recurrent malignant pleural effusions.  Respiration. 1995;  62 21-26
    CrossrefPubMedGoogle Scholar
  • 128 Hillerdal G, Kiviloog J, Nöu E, Steinholtz L. Corynebacterium parvum in malignant pleural effusion: a randomized prospective study.  Eur J Respir Dis. 1986;  69 204-206
    PubMedGoogle Scholar
  • 129 McLeod D T, Calverley P M, Millar J W, Horne N W. Further experience of Corynebacterium parvum in malignant pleural effusion.  Thorax. 1985;  40 515-518
    CrossrefPubMedGoogle Scholar
  • 130 Senyiğit A, Bayram H, Babayiğit C, Topçu F, Balci A E, Satici O. Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases.  Respiration. 2000;  67 623-629
    CrossrefPubMedGoogle Scholar
  • 131 Chella A, Ribechini A, Dini P, Adamo C, Mussi A, Angeletti C A. Treatment of malignant pleural effusion by percutaneous catheter drainage and chemical pleurodesis.  [in Italian] Minerva Chir. 1994;  49(11) 1077-1082
    PubMedGoogle Scholar
  • 132 Barbetakis N, Antoniadis T, Tsilikas C. Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer.  World J Surg Oncol. 2004;  2 16
    CrossrefPubMedGoogle Scholar
  • 133 Barbetakis N, Vassiliadis M, Kaplanis K, Valeri R, Tsilikas C. Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer.  BMC Palliat Care. 2004;  3 4
    CrossrefPubMedGoogle Scholar
  • 134 Kelly J, Holmes E C, Rosen G. Mitoxantrone for malignant pleural effusion due to metastatic sarcoma.  Surg Oncol. 1993;  2 299-301
    CrossrefPubMedGoogle Scholar
  • 135 Wilkins III H E, Connolly M M, Grays P, Marquez G, Nelson D. Recombinant interferon alpha-2b in the management of malignant pleural effusions.  Chest. 1997;  111 1597-1599
    CrossrefPubMedGoogle Scholar
  • 136 Sartori S, Trevisani L, Nielsen I, Tassinari D, Abbasciano V. Intracavitary bleomycin vs interferon in the management of malignant pleural effusions.  Chest. 1998;  113 1145-1146
    CrossrefPubMedGoogle Scholar
  • 137 Ren S, Terman D S, Bohach G et al.. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.  Chest. 2004;  126 1529-1539
    CrossrefPubMedGoogle Scholar
  • 138 Kasahara K, Shibata K, Shintani H et al.. Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer.  Anticancer Res. 2006;  26 1495-1499
    PubMedGoogle Scholar
  • 139 Luh K T, Yang P C, Kuo S H, Chang D B, Yu C J, Lee L N. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial.  Cancer. 1992;  69 674-679
    CrossrefPubMedGoogle Scholar

John E HeffnerM.D. 

Providence Portland Medical Center

5050 NE Hoyt St., Ste. 540, Portland, OR 97213

Email: John_heffner@mac.com

      >